IRIS
IACOBELLI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.607
EU - Europa 6.116
AS - Asia 5.814
SA - Sud America 786
Continente sconosciuto - Info sul continente non disponibili 418
AF - Africa 93
OC - Oceania 4
Totale 23.838
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.260
SG - Singapore 2.439
CN - Cina 1.545
UA - Ucraina 967
IE - Irlanda 842
GB - Regno Unito 782
IT - Italia 722
RU - Federazione Russa 714
BR - Brasile 638
SE - Svezia 634
TR - Turchia 605
FR - Francia 597
VN - Vietnam 479
DE - Germania 373
IN - India 281
FI - Finlandia 217
CA - Canada 156
BD - Bangladesh 88
HK - Hong Kong 68
PL - Polonia 53
MX - Messico 49
AR - Argentina 45
BE - Belgio 43
JP - Giappone 43
IQ - Iraq 42
KR - Corea 33
NL - Olanda 31
ZA - Sudafrica 31
ES - Italia 30
IL - Israele 29
EC - Ecuador 25
LT - Lituania 24
CZ - Repubblica Ceca 22
CO - Colombia 21
UZ - Uzbekistan 21
ID - Indonesia 19
PK - Pakistan 19
AT - Austria 17
JM - Giamaica 17
VE - Venezuela 17
SV - El Salvador 16
CR - Costa Rica 15
GP - Guadalupe 15
GT - Guatemala 15
NI - Nicaragua 15
TT - Trinidad e Tobago 15
HN - Honduras 12
IR - Iran 12
SA - Arabia Saudita 12
AE - Emirati Arabi Uniti 11
EG - Egitto 11
EU - Europa 11
PH - Filippine 11
CL - Cile 10
PE - Perù 10
SC - Seychelles 10
MA - Marocco 9
PY - Paraguay 9
CH - Svizzera 8
JO - Giordania 8
KE - Kenya 8
UY - Uruguay 8
AL - Albania 7
EE - Estonia 7
TN - Tunisia 7
AZ - Azerbaigian 6
CW - ???statistics.table.value.countryCode.CW??? 6
MY - Malesia 6
PR - Porto Rico 6
GR - Grecia 5
NP - Nepal 5
DO - Repubblica Dominicana 4
LB - Libano 4
PT - Portogallo 4
RO - Romania 4
SN - Senegal 4
TH - Thailandia 4
AO - Angola 3
AU - Australia 3
DZ - Algeria 3
ET - Etiopia 3
HU - Ungheria 3
KG - Kirghizistan 3
OM - Oman 3
PS - Palestinian Territory 3
RS - Serbia 3
TW - Taiwan 3
BB - Barbados 2
BH - Bahrain 2
BM - Bermuda 2
BO - Bolivia 2
BY - Bielorussia 2
DK - Danimarca 2
GD - Grenada 2
GE - Georgia 2
KH - Cambogia 2
NG - Nigeria 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BZ - Belize 1
Totale 23.421
Salva come PNG Salva come JPEG
Città #
Singapore 1.807
San Jose 1.138
Jacksonville 1.052
Chandler 1.039
Dublin 836
Southend 552
Ashburn 511
Dallas 424
Council Bluffs 383
Princeton 380
Beijing 346
Izmir 327
Nanjing 304
Santa Clara 268
Los Angeles 247
The Dalles 188
Wilmington 178
Cambridge 177
Buffalo 152
Ho Chi Minh City 150
New York 144
Tongling 138
Boardman 134
Ann Arbor 127
Nanchang 109
Dearborn 105
Hanoi 101
Altamura 91
Moscow 87
North Bergen 71
Phoenix 70
Chieti 67
Woodbridge 63
São Paulo 61
Munich 59
Hong Kong 58
Hebei 52
Columbus 50
Shenyang 49
Orem 47
Pescara 47
Tianjin 46
Houston 45
Brooklyn 43
Brussels 42
Kunming 42
Chicago 40
Atlanta 39
Rome 39
Tokyo 38
Denver 37
Redondo Beach 37
Milan 35
Boston 34
London 34
Chennai 32
Montreal 32
Stockholm 32
Kimball 30
Seoul 30
Jiaxing 29
Warsaw 29
Norwalk 27
Toronto 27
Dong Ket 24
Poplar 24
Hangzhou 23
Hefei 23
Johannesburg 23
Nuremberg 23
San Francisco 23
Changsha 22
Frankfurt am Main 21
Helsinki 21
St Louis 21
Manchester 20
Tashkent 20
Da Nang 19
Falls Church 19
Kocaeli 19
Washington 19
Grevenbroich 18
Brno 17
Haiphong 17
Montesilvano 17
Rio de Janeiro 17
Turku 17
Baghdad 16
Irving 16
Mexico City 16
Amsterdam 15
Collecorvino 15
Hyderabad 15
Managua 15
Philadelphia 15
San Mateo 15
Silver Spring 15
Augusta 14
Belo Horizonte 14
Jinan 14
Totale 13.670
Salva come PNG Salva come JPEG
Nome #
90K (Mac-2 BP) in human milk 255
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 224
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 206
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 199
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 198
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 190
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 189
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 187
An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. 185
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 184
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 184
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 181
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 179
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 177
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 174
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 172
ERBB3 BINDING ANTIBODY 171
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 171
Prognostic relevance of LGALS3BP in human colorectal carcinoma 171
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 170
Improvement of urinary tract symptoms and quality of life in benign prostate hyperplasia patients associated with consumption of a newly developed whole tomato-based food supplement: a phase II prospective, randomized double-blinded, placebo-controlled study 167
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 165
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 164
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 164
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 163
Analisi dello stato mutazionale di K-RAS: un nuovo strumento per la selezione dei pazienti candidati a terapia con anticorpi anti-EGFR 162
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 162
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 157
Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants 157
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 156
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 155
New Targets for Therapy in Pancreatic Cancer 155
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 155
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 154
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 153
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 152
Novel inhibitors of pvhl-elongin c binding 152
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 148
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 146
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 146
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 146
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 146
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications 144
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 144
A Stochastic Model for the HIV/AIDS Dynamic Evolution 142
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 142
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target 141
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 141
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 141
Unknown primary tumors 140
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 139
Increased levels of soluble P-selectin in hypercholesterolemic patients 139
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma 139
LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth 137
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 136
Tyrosine kinase inhibitors 135
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 135
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. 134
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 133
Prognostic value of 90K protein in HIV infection 131
Axillary Lymph Node Nanometastases are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients 131
Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. 131
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 131
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 130
Prognostic value of gender and primary tumor location in metastatic colon cancer 129
Prognostic value of a novel circulating serum 90K antigen in breast cancer 128
DNA ploidy and S-phase fraction in pulmonary carcinoids. 128
Tumor-derived microvesicles: The metastasomes. 128
Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma 127
Surgical treatment of adrenal metastases from non small cell lung cancer 127
[Hairy cell leukemia: prognosis and treatment] 127
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 127
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 127
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 127
Role of 90K protein in asthma and TH2-type cytokine expression. 126
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 126
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 125
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 125
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 125
Elevated Plasma Levels of 90K (Mac-2 BP) Immunostimulatory Glycoprotein in HIV-1-Infected Children 124
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 123
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 123
Phospholipase Cgamma1 is required for metastasis development and progression 122
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 122
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma 121
Combined therapy in pancreatic cancer 120
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 120
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 120
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 119
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 119
The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. 119
A stochastic model for evaluating the HIV anti-retroviral treatment patient cost: a case study 119
Inhibition of the Phosphatidylinositol 3-kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects. 119
Immunohistochemical and serological 90K/Mac-2BP detection in hepatocellular carcinoma patients: different behaviour of two monoclonal antibodies 118
HCV genotype and serum 90K levels: host and virus related factors predict response to a-ifn therapy 117
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1 117
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 117
Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. 117
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 116
Combinations of biological response modifiers: rationale and clinical responses. 116
Totale 14.618
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.972
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.972
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022569 0 0 0 0 89 16 15 52 64 14 93 226
2022/20232.769 208 286 172 351 313 589 157 214 321 24 73 61
2023/20241.204 108 37 98 58 66 353 259 39 14 23 16 133
2024/20253.594 198 747 608 89 64 95 123 189 317 185 391 588
2025/20266.618 545 352 700 786 566 489 1.109 373 663 612 323 100
2026/20272.355 101 368 390 1.086 410 0 0 0 0 0 0 0
Totale 23.838